Get startedLog in
    Picture of Eli Lilly and logo

    LLY — Eli Lilly and News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Lilly Presents First Clinical Data In Platinum-Sensitive Ovarian Cancer For Its Investigational, Next-Generation, Frα-Targeting ADC

    Picture of Eli Lilly and logoEli Lilly and
    24/10/2026 07:37
    BRIEF-Lilly Presents First Clinical Data In Platinum-Sensitive Ovarian Cancer For Its Investigational, Next-Generation, Frα-Targeting ADC
    Oct 24 (Reuters) - Eli Lilly and Company LLY.N:
    • LILLY PRESENTS FIRST CLINICAL DATA IN PLATINUM-SENSITIVE OVARIAN CANCER FOR ITS INVESTIGATIONAL, NEXT-GENERATION, FRΑ-TARGETING ADC AT ESMO 2026
    • ELI LILLY- PHASE 1 DATA ACHIEVED CONFIRMED OBJECTIVE RESPONSE RATE OF 79% & DISEASE CONTROL RATE OF 100% IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER
    Source text: [ID:]
    Further company coverage: LLY.N

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Eli Lilly and

    See all news